Litchfield Hills Research Comments on Adial Pharmaceuticals, Inc.’s Q1 2023 Earnings (NASDAQ:ADIL)

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL – Get Rating) – Investment analysts at Litchfield Hills Research issued their Q1 2023 earnings per share estimates for shares of Adial Pharmaceuticals in a research report issued to clients and investors on Monday, April 3rd. Litchfield Hills Research analyst T. O’neill expects that the company will post earnings of ($0.14) per share for the quarter. The consensus estimate for Adial Pharmaceuticals’ current full-year earnings is ($0.19) per share. Litchfield Hills Research also issued estimates for Adial Pharmaceuticals’ Q2 2023 earnings at ($0.11) EPS, Q3 2023 earnings at ($0.14) EPS and Q4 2023 earnings at ($0.11) EPS.

Get Adial Pharmaceuticals alerts:

Adial Pharmaceuticals Trading Down 5.5 %

Shares of ADIL stock opened at $0.32 on Wednesday. Adial Pharmaceuticals has a 1-year low of $0.20 and a 1-year high of $2.09. The company has a market capitalization of $9.06 million, a price-to-earnings ratio of -0.61 and a beta of 0.95. The stock’s fifty day simple moving average is $0.41 and its 200-day simple moving average is $0.34.

Institutional Trading of Adial Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Citadel Advisors LLC grew its stake in shares of Adial Pharmaceuticals by 1,156.2% in the 3rd quarter. Citadel Advisors LLC now owns 265,062 shares of the company’s stock valued at $93,000 after purchasing an additional 243,962 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Adial Pharmaceuticals by 74.6% during the 4th quarter. Renaissance Technologies LLC now owns 251,886 shares of the company’s stock valued at $54,000 after purchasing an additional 107,656 shares in the last quarter. Virtu Financial LLC lifted its stake in Adial Pharmaceuticals by 142.7% in the 3rd quarter. Virtu Financial LLC now owns 77,694 shares of the company’s stock valued at $27,000 after acquiring an additional 45,681 shares in the last quarter. Millennium Management LLC acquired a new position in shares of Adial Pharmaceuticals during the 2nd quarter worth approximately $53,000. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new position in shares of Adial Pharmaceuticals during the 1st quarter worth approximately $70,000. Institutional investors and hedge funds own 7.42% of the company’s stock.

Adial Pharmaceuticals Company Profile

(Get Rating)

Adial Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company, which focuses on the treatment of alcohol use disorder. Its lead product is AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson in November 2010 and is headquartered in Charlottesville, VA.

Further Reading

• Get a free copy of the StockNews.com research report on Adial Pharmaceuticals (ADIL)
• Penny Stock Wag! Group Co. Has Solid Sell-Side Support
• Staples Stocks Get Lift From Conagra Results, New Highs In Sight
• SGH Bottomed, But Can It Reverse And Move Higher? 
• Is Pinterest Showing Signs of an Improving Ad Market?
• At 3x Earnings, Avis Budget Is Worth Taking for a Spin

Receive News & Ratings for Adial Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adial Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.